▎WuXiEdited by Kant Content Team

Recently, Eli Lilly and Company announced positive results from a Phase 3 trial of its investigational IL-13 inhibitor lebrikizumab for the treatment of patients with moderate to severe atopic dermatitis (commonly known as eczema). Analysis showed that treatment with lebrikizumab alleviated skin symptoms and itching in patients.The efficacy results shown in the lebrikizumab trial are consistent with the data from another Phase 3 trial of the drug.The detailed efficacy and safety results of the study will be shared at future medical conferences.

The initial 16-week data from this study evaluated 50 patients with moderate to severe atopic dermatitis and darker skin tones (measured by the Fitzpatrick scale), including those who self-identified as Black or African American (80%), Asian (14%), American Indian or Alaska Native (6%). Among the 50 patients, 11 self-identified as Hispanic/Latino (22%), while the remaining 39 self-identified as non-Hispanic/non-Latino (78%). All patients initially received a 500 mg subcutaneous injection of lebrikizumab, followed by 250 mg administered subcutaneously every two weeks starting at week two until week 16. The results at week 16 of this trial were consistent with the 16-week results from the previous ADhere and ADvocate 1 & 2 trials:

• 68% of patients achieved the primary endpoint of the trial, with a 75% reduction in the Eczema Area and Severity Index (EASI-75) relative to baseline.

• 46% of patients achieved a 90% reduction in the Eczema Area and Severity Index (EASI-90) from baseline.

• 39% of patients achieved clear or almost clear skin symptoms (Investigator's Global Assessment [IGA] score of 0 or 1) and showed at least a two-grade improvement from baseline.

• 56% of patients experienced clinically meaningful relief from itching.(Improvement in the Pruritus Numerical Rating Scale [PNRS] ≥4 points).

In terms of safety, no new safety signals or serious adverse events were observed.

Lebrikizumab is an innovative monoclonal antibody drug that can bind to IL-13 with high affinity and high specificity, thereby preventing the formation of the IL-13Rα1/IL-4Rα complex and inhibiting the signaling pathway mediated by this receptor complex.Previously, lebrikizumab was granted Fast Track designation by the U.S. FDA for the treatment of adult and adolescent patients with moderate to severe atopic dermatitis.

Everyone is watching

▲To learn more about the application of cutting-edge technologies in the biopharmaceutical industry, please long-press and scan the QR code above to access "WuXi Live Studio" and watch live discussions and exciting replays on related topics.